RECRUITING

Clinical Research in ALS Study

Conditions

Amyotrophic Lateral Sclerosis genetics biomarkers pre-symptomatic natural history

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

CRiALS is an umbrella protocol through which people are recruited to participate in a range of research studies being conducted by the ALS Research Collaboration (ARC).

Official Title

Clinical Research in Amyotrophic Lateral Sclerosis

Quick Facts

Study Start:2005-02

Study Completion:2027-12

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT00136500

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. At least 18 years of age. 2. Member of at least one of the following categories: 1. Individuals affected with ALS or a related neurodegenerative disease (sporadic or familial) 2. Unaffected individuals from fALS pedigrees, including pre-symptomatic individuals at genetic risk for ALS or individuals from pedigrees of ALS related diseases. 3. Healthy controls 3. Able and willing to comply with relevant procedures.	1. Subject has a condition or is in a situation which, in the PI's opinion, could confound the study finding or may interfere significantly with the individual's participation and compliance with the study protocol -- including but not limited to neurological, psychological and/or medical conditions (e.g., multiple sclerosis, neuropathy, myelopathy).

Inclusion Criteria

Exclusion Criteria

1. At least 18 years of age.
2. Member of at least one of the following categories:
1. Individuals affected with ALS or a related neurodegenerative disease (sporadic or familial)
2. Unaffected individuals from fALS pedigrees, including pre-symptomatic individuals at genetic risk for ALS or individuals from pedigrees of ALS related diseases.
3. Healthy controls
3. Able and willing to comply with relevant procedures.

1. Subject has a condition or is in a situation which, in the PI's opinion, could confound the study finding or may interfere significantly with the individual's participation and compliance with the study protocol -- including but not limited to neurological, psychological and/or medical conditions (e.g., multiple sclerosis, neuropathy, myelopathy).

Contacts and Locations

Study Contact

Anne-Laure Grignon, MD

CONTACT

888-413-9315

fals@med.miami.edu

Principal Investigator

Michael Benatar, MD, PhD.

PRINCIPAL_INVESTIGATOR

University of Miami

Study Locations (Sites)

University of Miami

Miami, Florida, 33136

United States

Collaborators and Investigators

Sponsor: University of Miami

Michael Benatar, MD, PhD., PRINCIPAL_INVESTIGATOR, University of Miami

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2005-02

Study Completion Date2027-12

Study Record Updates

Study Start Date2005-02

Study Completion Date2027-12

Terms related to this study

Keywords Provided by Researchers

genetics
biomarkers
pre-symptomatic
natural history

Additional Relevant MeSH Terms

Amyotrophic Lateral Sclerosis